Screener
Allogene Therapeutics ALLO PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 273,293 | 257,749 |
| Long-term investments | — | 8,043 |
| Operating lease right-of-use asset | 38,819 | 39,888 |
| Property and equipment, net | 70,023 | 72,839 |
| Deposit placed in escrow | — | 23,479 |
| Restricted cash | 10,292 | 10,292 |
| Other long-term assets | 3,531 | 3,615 |
| Total assets | $395,958 | $415,905 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's PP&E (net)?
- Allogene Therapeutics (ALLO) reported PP&E (net) of $70.02M in Q1 2026.
- How has Allogene Therapeutics's PP&E (net) changed year-over-year?
- Allogene Therapeutics's PP&E (net) decreased by 15.6% year-over-year, from $82.99M to $70.02M.
- What is the long-term trend for Allogene Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Allogene Therapeutics's PP&E (net) has grown at a -9.3% compound annual growth rate (CAGR), from $118.84M to $72.84M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Allogene Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude